Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics

Table 1 Recurrent sCNAs in peripheral blood primary CLL samples

sCNA	Frequency in CLL (%)	Likely target	Frequency in MBL (%)	More common *IGHV* status	Prognostic significance
del(13q14)	57 to 61 [26, 27]	miR-15a/16, encoded in an intron of DLEU2 [8]. Its deletion leads to the release of BCL2 from microRNA-mediated down-regulation [28]	48 [112]	None	Good [9]
del(11q22.3)	6 to 27 [26, 27]	ATM, BIRC3	Rare	Unmutated	Poor [9]
Trisomy 12	11 to 12 [26, 27]	Unknown [7]	20 [112]	None	None [9]
del(17p)	6 to 8 [26, 27]	TP53	Rare	Unmutated	Poor [9]
amp(2p)	7 [27]	XPO1, BCL11A	Unknown	Unmutated	None [27]
amp(8q24.21)	5 [26, 27]	MYC	Unknown	Unmutated	Poor [26, 27]
del(15q15.1)	4 [27]	MGA	Unknown	Unknown	None [27]
del(10)(q24)	2 [27]	NFKB2	Unknown	Unknown	Unknown
del(18p)	3 [27]	Unknown	Unknown	Unmutated [27]	Unknown
del(6q)	7 [27]	Unknown	Unknown	Unknown	Unknown
amp(3q26.32)	6 [26]	PIK3CA	Unknown	Unknown	Poor [26]
del(8p)	5 [23, 26]	Unknown	Unknown	Unknown	Poor [26]

amp, amplification; sCNA, somatic copy number alterations; MBL, monoclonal B-cell lymphocytosis.

ISSN: 1756-994X